Personal information

No personal information available

Activities

Collapse all

Works (9)

Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group

American Journal of Hematology
2024-10 | Journal article
DOI: 10.1002/ajh.27425
Contributors: Eirini Katodritou; Dimitra Dalampira; Sosana Delimpasi; Ioannis Ntanasis‐Stathopoulos; Fryni Karaolidou; Annita‐Ioanna Gkioka; Vasiliki Labropoulou; Emmanouil Spanoudakis; Theodora Triantafyllou; Maria Kotsopoulou et al.
Source: check_circle
Crossref

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Blood Advances
2024-10-08 | Journal article
DOI: 10.1182/bloodadvances.2024013101
Contributors: Meletios A. Dimopoulos; Daniel Coriu; Sosana Delimpasi; Ivan Špička; Terry Upchurch; Belle Fang; Rakhshandra Talpur; Edward Faber; Meral Beksac; Xavier Leleu
Source: check_circle
Crossref

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

American Journal of Hematology
2024-09 | Journal article
DOI: 10.1002/ajh.27382
Contributors: Sosana Delimpasi; Meletios A. Dimopoulos; Jan Straub; Argiris Symeonidis; Luděk Pour; Roman Hájek; Cyrille Touzeau; Viralkumar K. Bhanderi; Jesus G. Berdeja; Petr Pavlíček et al.
Source: check_circle
Crossref

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

Leukemia & Lymphoma
2024-05-11 | Journal article
DOI: 10.1080/10428194.2024.2322030
Contributors: Aurore Perrot; Sosana Delimpasi; Emmanouil Spanoudakis; Ulf Frølund; Angelo Belotti; Albert Oriol; Philippe Moreau; Ian McFadden; Qing Xia; Mukta Arora et al.
Source: check_circle
Crossref

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study

American Journal of Hematology
2023-09 | Journal article
DOI: 10.1002/ajh.27001
Contributors: Efstathios Kastritis; Evangelos Terpos; Argiris Symeonidis; Vasiliki Labropoulou; Sosana Delimpasi; Katia Mancuso; Elena Zamagni; Eirini Katodritou; Elena Rivolti; Marie‐Christine Kyrtsonis et al.
Source: check_circle
Crossref

Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group

American Journal of Hematology
2023-05 | Journal article
DOI: 10.1002/ajh.26891
Contributors: Eirini Katodritou; Efstathios Kastritis; Dimitra Dalampira; Sosana Delimpasi; Emmanouil Spanoudakis; Vasiliki Labropoulou; Ioannis Ntanasis‐Stathopoulos; Annita‐Ioanna Gkioka; Nikos Giannakoulas; Nikolaos Kanellias et al.
Source: check_circle
Crossref

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

American Journal of Hematology
2023-01 | Journal article
DOI: 10.1002/ajh.26602
Contributors: Meletios A. Dimopoulos; Philippe Moreau; Bradley Augustson; Nelson Castro; Tomas Pika; Sosana Delimpasi; Javier De la Rubia; Angelo Maiolino; Tony Reiman; Joaquin Martinez‐Lopez et al.
Source: check_circle
Crossref

Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial

American Journal of Hematology
2022-04 | Journal article
DOI: 10.1002/ajh.26480
Contributors: Evangelos Terpos; Meletios A. Dimopoulos; Mario Boccadoro; Sosana Delimpasi; Meral Beksac; Eirini Katodritou; Philippe Moreau; Alessandra Pompa; Argiris Symeonidis; Jelena Bila et al.
Source: check_circle
Crossref

Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

American Journal of Hematology
2022-03 | Journal article
DOI: 10.1002/ajh.26434
Contributors: Sosana Delimpasi; Maria Victoria Mateos; Holger W. Auner; Maria Gavriatopoulou; Meletios A. Dimopoulos; Hang Quach; Halyna Pylypenko; Roman Hájek; Xavier Leleu; Tuphan Kanti Dolai et al.
Source: check_circle
Crossref

Peer review (2 reviews for 2 publications/grants)

Review activity for BioDrugs. (1)
Review activity for The lancet. (1)
How many people are using ORCID?